# Enhanced Transcutaneous Delivery of Betamethasone for the Treatment of Vitiligo

> **NCT05233735** · NA · UNKNOWN · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Vitiligo

## Interventions

- **OTHER:** Enhanced Transcutaneous Delivery of Topical Betamethasone after the treatment with Tixel
- **OTHER:** Topical treatment

## Key facts

- **NCT ID:** NCT05233735
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05233735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05233735, "Enhanced Transcutaneous Delivery of Betamethasone for the Treatment of Vitiligo". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05233735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*